Tamarack Advisers LP bought a new position in DermTech, Inc. (NASDAQ:DMTK – Get Rating) during the 1st quarter, Holdings Channel.com reports. The institutional investor bought 50,000 shares of the company's stock, valued at approximately $734,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Swiss National Bank boosted its stake in DermTech by 2.9% during the fourth quarter. Swiss National Bank now owns 39,100 shares of the company's stock valued at $618,000 after buying an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in DermTech by 16.9% in the 1st quarter. JPMorgan Chase & Co. now owns 18,797 shares of the company's stock worth $276,000 after acquiring an additional 2,715 shares in the last quarter. Wolverine Asset Management LLC purchased a new stake in DermTech in the 4th quarter worth about $43,000. Russell Investments Group Ltd. raised its stake in shares of DermTech by 22.6% during the 1st quarter. Russell Investments Group Ltd. now owns 14,847 shares of the company's stock worth $217,000 after purchasing an additional 2,734 shares in the last quarter. Finally, Jacob Asset Management of New York LLC increased its holdings in shares of DermTech by 6.0% during the 4th quarter. Jacob Asset Management of New York LLC now owns 53,422 shares of the company's stock valued at $844,000 after acquiring an additional 3,007 shares during the last quarter. Institutional investors own 75.12% of the company's stock.

DermTech Trading Down 2.8 %

NASDAQ:DMTK traded down $0.16 on Monday, hitting $5.55. The company's stock had a trading volume of 5,118 shares, compared to its average volume of 810,018. The stock has a fifty day moving average of $6.47 and a two-hundred day moving average of $9.33. The firm has a market capitalization of $166.72 million, a P/E ratio of -1.55 and a beta of 1.39. DermTech, Inc. has a one year low of $4.18 and a one year high of $38.97.

Wall Street Analysts Forecast Growth

DermTech Company Profile

(Get Rating)

DermTech, Inc, a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.

Further Reading

• Get a free copy of the StockNews.com research report on DermTech (DMTK)
• Oil Services: Who Will Lead The Rebound?
• Analog Devices Reveals Semiconductor Demand Problems
• Three Ways To Find Hot Stocks In A Tepid Market
• Here are the Multiple Stages of a Bear Market
• 3 August Earnings Reports With 'Wow' Potential

Want to see what other hedge funds are holding DMTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DermTech, Inc. (NASDAQ:DMTK – Get Rating).

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with MarketBeat.com's FREE daily email newsletter.